Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

Wanatpreeya PhongsamartWatsamon JantarabenjakulSasitorn ChantaratinSuvaporn AnugulruengkittPiyarat SuntarattiwongPakpen SirikuttPope KosalaraksaAlan MaleesatharnKulkanya Chokephaibulkit

Published in: Journal of the International AIDS Society (2022)

A high proportion of adolescents (>92%) remained virologically suppressed up to 48 weeks after switching from EFV to RPV along with no significant change in CD4 cell counts. RPV was well tolerated and associated with improvements in metabolic profiles and executive function.

Keyphrases

hiv infected
hiv infected patients
antiretroviral therapy
young adults
hiv positive
human immunodeficiency virus
physical activity
hiv aids
single cell
cell therapy
hepatitis c virus
hiv testing
bone marrow
peripheral blood